Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …

Single-cell technologies have enabled the characterization of the tumour microenvironment
at unprecedented depth and have revealed vast cellular diversity among tumour cells and …

Neoadjuvant immune-checkpoint blockade therapy only benefits a limited fraction of patients
with glioblastoma multiforme (GBM). Thus, targeting other immunomodulators on myeloid …

Glioblastomas are aggressive primary brain tumors with an inherent resistance to T cell-
centric immunotherapy due to their low mutational burden and immunosuppressive tumor …

Clinically relevant immunological biomarkers that discriminate between diverse
hypofunctional states of tumor-associated CD8+ T cells remain disputed. Using multiomics …

Glioblastomas are aggressive brain tumors that are largely immunotherapy resistant. This is
associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T …

The advent of immunotherapy has made an indelible mark on the field of cancer therapy,
especially the application of immune checkpoint inhibitors in clinical practice. Although …

Tumor-associated myeloid cells (TAMCs) are among the most important immune cell
populations in the tumor microenvironment, and play a significant role on the efficacy of …

In comparison with responses in recurrent glioblastoma (rGBM), the intracranial response of
brain metastases (BrM) to immune checkpoint blockade (ICB) is less well studied. Here, we …